6 reasons to buy Teva Pharmaceuticals stock sooner than later

Key PointsTeva Pharmaceuticals is a global generic drug maker that is getting ready to form a monthly breakout of its 5-year rectangle range.Teva was upgraded to an Outperform rating by Piper Sandler with a $19 price target.Teva beats its recent Q4 2023 EPS estimates by 23 cents as revenue rose 15% YoY as shares traded at just 5.6X forward earnings.5 stocks we like better than Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries Ltd. NYSE: TEVA is a global pharmaceutical company in the medical secto ...